HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-11-19FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s supplemental application for tenofovir disoproxil fumarate.
-
CLINICAL_TRIALS trial_result · 2019-11-14Clinical Trial Update: Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia [Phase 4]
Phase 4 clinical trial evaluating genotypic tropism testing in proviral DNA to guide CCR5 antagonist therapy in people with undetectable HIV…
-
CLINICAL_TRIALS research · 2019-11-14Clinical Trial Update: Drug Interactions Between Silimarine and Darunavir/Ritonavir [Phase 4]
Clinical trial update investigating potential drug interactions between silimarine and darunavir/ritonavir in people with HIV (Phase 4; comp…
-
CLINICAL_TRIALS trial_result · 2019-11-04Clinical Trial Update: Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I [Phase 3]
A Phase 3 trial evaluating switching virologically suppressed HIV-1 patients with archived M184V/M184I mutations to an elvitegravir/cobicist…
-
CLINICAL_TRIALS trial_result · 2019-10-31Clinical Trial Update: Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals [NA]
Clinical trial update on raltegravir CSF pharmacodynamics in HIV-infected individuals; study terminated with results posted in 2019.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-10-31Clinical Trial Update: The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study [Phase 1]
Phase 1 pharmacokinetic study of maraviroc with darunavir/ritonavir administered once daily in HIV patients has completed; results posted in…
-
CLINICAL_TRIALS trial_result · 2019-10-30Clinical Trial Update: Kinetics of HIV-RNA Decay in Seminal Plasma of Men Treated by Dolutegravir at the Time of Primary HIV Infection [Phase 3]
A Phase 3 trial evaluating the kinetics of HIV-RNA decay in seminal plasma of men treated with dolutegravir at the time of primary HIV infec…
-
CLINICAL_TRIALS trial_result · 2019-10-30Clinical Trial Update: Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals [Phase 3]
Phase 3 trial evaluating 3HP regimens vs 6H in HIV-positive individuals with tuberculosis has completed.
-
CLINICAL_TRIALS trial_result · 2019-10-30Clinical Trial Update: Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002) [Phase 1]
Phase 1 single-dose safety and pharmacokinetics study of MK-4250 monotherapy in ART-naive HIV-1 infected participants; completed with result…
-
CLINICAL_TRIALS research · 2019-10-30Clinical Trial Update: Project IMPACT: Improving Memory Performance by Applying Cognitive Training [NA]
A completed clinical trial investigating cognitive training to improve memory performance in individuals with cocaine use disorders and HIV;…
-
FDA approval · 2019-10-29FDA Approved: SYMFI — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for SYMFI, the fixed-dose combination of efavirenz, lamivudine, and tenofovir disoproxil fumarat…
-
CLINICAL_TRIALS research · 2019-10-29Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants [Phase 3]
Phase 3 study evaluating long-acting injectable cabotegravir and rilpivirine for maintaining virologic suppression in HIV-1–infected partici…
-
CLINICAL_TRIALS trial_result · 2019-10-29Clinical Trial Update: AmB Dose for Cryptococcal Meningitis [Phase 3]
Phase 3 trial update examining AmB dose for cryptococcal meningitis; status is currently unknown.
-
FDA approval · 2019-10-24FDA Approved: TIVICAY — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for TIVICAY (dolutegravir) from ViiV Healthcare Company.
-
FDA approval · 2019-10-24FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) from ViiV Healthcare Company.
-
FDA label_change · 2019-10-24FDA Approved: JULUCA — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for JULUCA (dolutegravir sodium and rilpivirine hydrochloride) submitted by ViiV Healthcare Company,…
-
FDA approval · 2019-10-24FDA Approved: DOVATO — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for Dovato (dolutegravir and lamivudine) by ViiV Healthcare Company.
-
CLINICAL_TRIALS trial_result · 2019-10-22Clinical Trial Update: HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure [Phase 4]
A Phase 4 clinical trial update on HIV diagnosis and treatment at birth for newborns with high-risk exposure, completed.
-
CLINICAL_TRIALS trial_result · 2019-10-22Clinical Trial Update: To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection [NA]
Clinical trial assessing neuroinflammation and neurocognitive function in patients with acute hepatitis C and chronic HIV co-infection; stat…
-
CLINICAL_TRIALS trial_result · 2019-10-21Clinical Trial Update: Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa [Phase 4]
Phase 4 trial comparing boosted atazanavir with Truvada vs boosted darunavir with maraviroc and Kivexa in treatment-naive HIV-1 subjects ass…
-
CLINICAL_TRIALS trial_result · 2019-10-21Clinical Trial Update: Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed [Phase 4]
Phase 4 trial update evaluating switching to a fixed-dose combination of bictegravir/emtricitabine/tenofovir alafenamide in virologically su…
-
CLINICAL_TRIALS trial_result · 2019-10-18Clinical Trial Update: A Risky Sex Prevention Intervention for Middle School Age Minority Girls [NA]
A completed clinical trial from UNC Greensboro evaluating a risk reduction intervention for HIV prevention among middle school-age minority …
-
CLINICAL_TRIALS research · 2019-10-11Clinical Trial Update: Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function [Phase 1]
Phase 1 pharmacokinetics study of Bictegravir in adults with normal and impaired renal function completed.
-
FDA approval · 2019-10-10FDA Approved: PIFELTRO — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for PIFELTRO (doravirine) submitted by Merck Sharp & Dohme LLC, finalizing changes to the product la…
-
FDA approval · 2019-10-10FDA Approved: DELSTRIGO — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) from Merck Sharp & Dohme LLC…